Drug intelligence / Profile preview

SAPU 006

Development stage: Unknown
Lead developer: Oncotelic Therapeutics
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

SAPU 006 (also known as Sapu-006 or docetaxel deciparticle) is an ultra-small, intravenous nanoparticle formulation of docetaxel, a semi-synthetic taxane analogue. Developed using Sapu Nano's proprietary Deciparticle™ nanomedicine platform, SAPU 006 encapsulates docetaxel into amphiphilic constructs measuring below 20 nanometers. This ultra-small size is designed to optimize tissue distribution, enhance tumor penetration, and improve the therapeutic index of docetaxel by overcoming delivery barriers associated with poorly water-soluble oncology agents. SAPU 006 is being developed for the treatment of solid tumors, with primary indications including prostate cancer and gastric cancer.

Other names: docetaxel Deciparticle

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SAPU 006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAPU 006.